AstraZeneca and Oxford University aim to have an updated vaccine to address the different CCP virus variants by the autumn, according to an executive for the UK-based drugmaker. Research chief Mene Pangalos said they wanted a next-generation vaccine “as rapidly as possible” to tackle new variants of the Chinese Communist Party (CCP) virus, commonly called the novel coronavirus. “We’re very much aiming to try and have something ready by the autumn, so this year,” said Pangalos. That time-frame includes lab work and clinical studies. Pangalos disclosed the goal on the same day AstraZeneca published research that showed their vaccine can reduce transmission by 67 percent. The paper, which is still under review, also found that just one dose of the vaccine provided 100 percent protection from severe symptoms of the disease. The UK has pitted one of the highest levels of vaccinations in the world against one of the highest levels …